Completed PHASE2 INTERVENTIONAL 4-arm NCT02837198

Study of FYU-981 in Hyperuricemia (Effect on Two Hyperuricemic Types)

Seven-day Repeated Dose Clinical Pharmacological Study of FYU-981 Administered to Hyperuricemia

Sponsor: Fuji Yakuhin Co., Ltd.

Updated 7 times since 2017 Last updated: Aug 20, 2018 Started: Jul 31, 2016 Primary completion: Aug 31, 2017 Completion: Mar 31, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02837198, this PHASE2 trial focuses on Hyperuricemia and remains completed. Sponsored by Fuji Yakuhin Co., Ltd., it has been updated 7 times since 2016, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Sep 2018 — Jan 2021 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Jun 2018 — Sep 2018 [monthly]

Active Not Recruiting PHASE2

▶ Show 2 earlier versions

Oct 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Jan 2017 — Oct 2017 [monthly]

Recruiting PHASE2

First recorded

Jul 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fuji Yakuhin Co., Ltd.

Data source: Fuji Yakuhin Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tokyo, Japan